← Back to Search

Monoclonal Antibodies

Drug：LM-102 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by LaNova Medicines Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (week 0) through approximately 1 year after first administration of lm102
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and works against CLDN18.2-positive advanced solid tumors.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (week 0) through approximately 1 year after first administration of lm102
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (week 0) through approximately 1 year after first administration of lm102 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Electrocardiogram (ECG)-QRS duration
Change in Electrocardiogram (ECG)-QT interval
Change in Electrocardiogram (ECG)-RR interval
+10 more
Secondary outcome measures
Area under the serum concentration versus time curve within one dosing interval (AUCtau)
Best of response (BOR)
Clearance (CL)
+11 more

Trial Design

5Treatment groups
Experimental Treatment
Group I: LM102 Dose Escalation Level 5, 40mg/kgExperimental Treatment1 Intervention
LM102 Dose Escalation Level 5, 40mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
Group II: LM102 Dose Escalation Level 4, 30mg/kgExperimental Treatment1 Intervention
LM102 Dose Escalation Level 4, 30mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
Group III: LM102 Dose Escalation Level 3, 20mg/kgExperimental Treatment1 Intervention
LM102 Dose Escalation Level 3, 20mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
Group IV: LM102 Dose Escalation Level 2, 10mg/kgExperimental Treatment1 Intervention
LM102 Dose Escalation Level 2, 10mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
Group V: LM102 Dose Escalation Level 1, 3mg/kgExperimental Treatment1 Intervention
LM102 Dose Escalation Level 1, 3mg/kg, enrolled CLDN 18.2 positive advanced solid tumors

Find a Location

Who is running the clinical trial?

LaNova Medicines LimitedLead Sponsor
8 Previous Clinical Trials
688 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of LM-102 in Subjects in Advanced Tumors
2021. "Study of LM-102 in Subjects in Advanced Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04735796.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top